Facebook
X
LinkedIn
Forward
ASTRO/KCA Joint Activity: Stereotactic Radiotherapy and Renal Cell Cancer, Overcoming Radioresistance and the Resistance to Radiate
This activity brings together an international panel and multidisciplinary expertise to discuss the emerging role of SABR to the primary in renal cell carcinoma (RCC). The activity focuses on patients who have localized disease treated for cure, and to a lesser extent the role of SABR to patients with oligometastatic RCC treated with "definitive intent." An overview of the historical concept of radioresistance in RCC and the rationale for SABR is introduced. Building on this, relevant epidemiology, comparative effectiveness, and health services data is reviewed. Indications for primary renal SABR are discussed within the hierarchy of alternative ablative/extirpative techniques. An overview of technical considerations and response assessment is provided, with a focus on different treatment platforms, immobilization techniques, motion management strategies, dose prescriptions and organ at risk constraints. These include discussion of limitations and common practical barriers faced in the delivery of SABR to primary RCC. Challenging scenarios such as the presence of a single kidney, IVC thrombus, and large/anatomically challenging tumors are discussed. Various clinical considerations for SABR within metastatic RCC are explored from a medical oncology and radiation oncology perspective, including its application for oligometastatic targets and the use of SABR to the primary as an alternative to cytoreductive nephrectomy. Finally, the early clinical experience of the MR-Linac platform for primary RCC is shared.
Topics:
- A Primer on Radiotherapy in Renal Cell Cancer
Nicholas G. Zaorsky, MD, MS - Technical Considerations, Response Assessment and Challenging Cases in Primary Renal SABR
Anna ME Bruynzeel, MD, PhD - Q&A for Anna Bruynzeel, MD, PhD
- Multidisciplinary Management from Urology Perspective
Brian Shuch, MD - From the IROCK Experience in Primary RCC to Expanding the Role in Oligometastatic RCC
Raquibul Hannan, MD, PhD - Multidisciplinary Management from Medical Oncology
Rana R. McKay, MD, FASCO - Kidney Cancer Case Discussions
Chad Tang, MD – Moderator
Full Panel
This activity is available from May 19, 2026, through 11:59 p.m. Eastern time on May 18, 2028.
The content was originally presented and recorded at the 2025 ASTRO Annual Meeting.
Target Audience
The activity is designed to meet the interests of medical oncologists, radiation oncologists, physicists, nurses, diagnostic radiologists, pathologists, radiation therapists, dosimetrists, radiation biologists and residents.
Learning Objectives
Upon completion of this activity, participants should be able to:
- Discuss the evidence to support SABR as a modality that overcomes perceived radioresistance of primary RCC.
- Review practical and technical considerations in the treatment of and surveillance following SABR for primary RCC.
- Discuss the role of novel systemic therapy, surgery and radiotherapy for oligometastatic RCC.
Moderator:
- •Shankar Siva, PhD, MBBS, FRANZCR, is employed by The University of Melbourne. Dr. Siva receives grant/research funding from Bayer Pharmaceuticals and Merck Sharp Dohme. Dr. Siva’s institution receives payment from AstraZeneca and Varian Medical Systems.
Speakers:
- Nicholas G. Zaorsky, MD, MS, is employed by Case Western Reserve School of Medicine. Dr. Zaorsky has no relevant financial relationship with ineligible companies to disclose.
- Anna ME Bruynzeel, MD, PhD, is employed by Amsterdam UMC. Dr. Bruynzeel has no relevant financial relationship with ineligible companies to disclose.
- Brian Shuch, MD, is employed by University of California, Los Angeles. Dr. Shuch receives grant/research funding and honoraria from Telix.
- Raquibul Hannan, MD, PhD, is employed by University of Texas Southwestern Medical Center. Dr. Hannan has no relevant financial relationship with ineligible companies to disclose.
- Rana R. McKay, MD, FASCO, is employed by University of California San Diego. Dr. McKay receives grant/research funding and honoraria from Ambrx, AstraZeneca, Bayer, Neomorph, Novartis, Pfizer, Telix, Blue Earth Diagnostics, BMS, Caris, Daiichi Sankya, Dendreon, Exelixis, SeaGen, Tempus, JNJ, Arcus, Eli Lilly, Merck, Tempus and Myovant.
- Chad Tang, MD, is employed by The University of Texas MD Anderson Cancer Center. Dr. Tang receives grant/research funding from Merck and Myriad Genetics. Dr. Tang owns copyrights/patents and receives royalties from Osler and Wolters Kluwer.
Planners:
- Malcolm Mattes, MD, is employed at Rutgers Cancer Institute. Dr. Mattes received research/grant funding from Gilead Sciences (relationship ended 8/30/2025). Dr. Mattes has no relevant financial relationship with ineligible companies.
- Parul Barry, MD, is employed by the University of Pittsburgh Medical Center. Dr. Barry has no relevant financial relationship with ineligible companies.
- Michael Haddock, MD, is employed by Mayo Clinic and has no relevant financial relationship with ineligible companies to disclose.
- Manisha Palta, MD, is employed by Duke Cancer Center and Duke University Hospital. Dr. Palta receives grant/research funding from Merck and Varian Medical Systems.
- Salma Jabbour, MD, is employed by Rutgers Cancer Institute. Dr. Jabbour receives grant/research funding from Merck & Co., Inc. and Beigene. Dr. Jabbour receives compensation/payment as a consultant with Radialogica and IMX Medical.
All relevant financial relationships have been mitigated.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Available Credit
- 1.25 AMA PRA Category 1 Credit™
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this Enduring material for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
Price
Course Fees:
ASTRO members must log in to the ASTRO website to view and receive the member rate.
- Nonmember: $149
- Member: $99
- Member-in-Training: $49
- Student/Graduate Student/PGY-1 Member: $49
- Postdoctoral Fellow Member: $49
If you are an ASTRO member from a low or lower-middle income country, as identified by the World Bank, you can receive a 50% discount off your corresponding registration for this activity. Please email [email protected] to inquire about the discount.
Policies:
No refunds, extensions, or substitutions will be made for those participants who, for any reason, have not completed the activity by the expiration date.
Participants using ASTRO Academy activities to satisfy the requirement of a Continuing Certification (MOC) program should verify the credit number and type and availability dates of any activity before making a purchase. No refunds, extensions, or substitutions will be made for participants who have purchased activities that do not align with their MOC requirement.
The activity and its materials will only be available on the ASTRO website until May 18, 2028, regardless of purchase date. At the expiration of the activity, participants will no longer have access to the activity or its materials. ASTRO reserves the right to remove an activity before its expiration date.
Required Hardware/software
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.